ADEF
CYTK icon

ABS Direct Equity Fund’s Cytokinetics CYTK Stock Holding History

ABS Direct Equity Fund’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273K Buy
+85
New +$6.1K 0.17% 91

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABS Direct Equity Fund's CYTK Position: Q2 2026 in Review

ABS Direct Equity Fund opened a new position in Cytokinetics (CYTK) in Q2 2026: 85 shares worth $273K. The stake represents 0.17% of the portfolio and ranks #91 among its holdings.

482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • ABS Direct Equity Fund held 85 shares of Cytokinetics worth $273K as of Q2 2026.
  • Cytokinetics was a new ABS Direct Equity Fund position in Q2 2026.
  • Cytokinetics made up 0.17% of ABS Direct Equity Fund's portfolio in Q2 2026, its #91 holding.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.